Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal what happens when cannabis users with psychosis go cold turkey

NCT ID NCT05445180

Knowledge-focused Sponsor: Douglas Mental Health University Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

This study looks at how stopping cannabis use for 28 days changes brain activity and memory in people with psychosis and in cannabis users without psychosis. Participants are randomly assigned to either quit cannabis or continue using, and undergo brain scans before and after the 28-day period. The goal is to understand the brain processes behind cannabis-related thinking problems, which could lead to better treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 134 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide informed consent in English or French * Heavy cannabis use (defined as weekly cannabis use for at six months) and/or DSM-5 diagnosis of CUD * Have a Full-Scale IQ ≥ 75 * Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only) * Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only) * Clinically stable (as measured by the PANSS-6, total score \<30) (psychosis patient arm only) Exclusion Criteria: * current SUD (other than CUD) * MRI contraindications * Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine * Current suicidal or homicidal ideation * Head injury requiring hospitalization or loss of consciousness \> 5 minutes * Current medical diseases that requires hospitalization or regular monitoring * Being pregnant * DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only) * Taking psychotropic medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis dependence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence cognitive disorder Cognitive Dysfunction Memory Disorders psychotic disorder Psychotic Disorders schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis dependence Cannabis use Cannabis use disorder Cognitive dysfunction Memory impairment Neuroimaging Psychotic disorders Schizophrenia; psychosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Douglas Mental Health University Institute

    RECRUITING

    Montreal, Quebec, H4H 1R3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.